
    
      Autologous hematopoietic stem cells from mobilized peripheral blood will be transduced ex
      vivo (outside the body) with a lentiviral vector carrying a correct copy of the deficient PKD
      gene. The corrected stem cells will be infused intravenously back to the patient with the
      goal of correcting the hematological manifestations of the disease.
    
  